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Abstract
Important oncological management decisions rely on kidney function assessed by serum creatinine–based estimated glomer-
ular filtration rate (eGFR). However, no large-scale multicenter comparisons of methods to determine eGFR in patients with
cancer are available. To compare the performance of formulas for eGFR based on routine clinical parameters and serum cre-
atinine not calibrated with isotope dilution mass spectrometry, we studied 3620 patients with cancer and 166 without cancer
who had their glomerular filtration rate (GFR) measured with an exogenous nuclear tracer at one of seven clinical centers.
The mean measured GFR was 86 mL/min. Accuracy of all models was center dependent, reflecting intercenter variability of
isotope dilution mass spectrometry–creatinine measurements. CamGFR was the most accurate model for eGFR (root-mean-
squared error 17.3 mL/min) followed by the Chronic Kidney Disease Epidemiology Collaboration model (root-mean-squared
error 18.2 mL/min).
Knowledge of kidney function measured as the glomerular fil-
tration rate (GFR) informs clinical practice (1). GFR can be accu-
rately measured (mGFR) using exogenous nuclear tracer
clearance, but in practice, is frequently estimated (eGFR) using
models based on routine clinical and biochemical data, specifi-
cally serum creatinine concentration. Creatinine is commonly
measured using Jaffe or enzymatic methods, which in turn are
calibrated using an isotope dilution mass spectrometry (IDMS)
standard or a non–IDMS standard (2).
Recently, we derived a new model for GFR (CamGFR) using
data from patients with cancer treated at the Cambridge
University Hospitals NHS Foundation Trust, United
Kingdom (3). CamGFR modeled GFR on a square root scale using
non-IDMS–creatinine and biometric patient data and estimated
GFR more accurately compared with other published models.
This gain increased accuracy in GFR-based carboplatin chemo-
therapy dose calculations (3). Here we validate these findings
for non-IDMS–creatinine-based estimation of GFR using multi-
center data from patients with and without cancer.
Data were from the University Hospitals NHS Foundation
Trusts in Cambridge, Southampton (4), and Manchester; Barts
Health NHS Trust, London; a combined Welsh dataset (5,6);
Western General Hospital, Edinburgh; and the Peter MacCallum
Cancer Centre, Melbourne (7). Data on age, sex, height, weight,
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serum creatinine concentration, histopathologically confirmed
cancer diagnosis, ethnicity, and mGFR were obtained. Either chro-
mium-51–labeled ethylenediamine tetraacetic acid (51Cr-EDTA) or
99mTc-diethylenetriaminepentaacetic acid (99mTc-DTPA) clear-
ance was used to measure GFR (8,9). Serum creatinine was deter-
mined by enzymatic or Jaffe methods within 30 days of the mGFR
date (Supplementary Table S1, available online). Adult patients
with creatinine levels between 0.20 mg/dL and 4.5 mg/dL were in-
cluded. From patients with multiple mGFR values, we included
only the first value by date. Body surface area (BSA) was calcu-
lated using the DuBois and DuBois equation (10). The study was
conducted at each institution according to its relevant regulatory
and ethical requirements.
We compared mGFR with eGFR provided by six published
models (CamGFR [3]; Martin [11]; Wright [12]; Mayo [13];
Modification of Diet in Renal Disease version 186 [14]; and
Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]
[15]), along with two models for creatinine clearance (Cockcroft-
Gault [16] and Jelliffe [17]).
To assess model performance, statistics were determined for
bias (residual median), precision (residual interquartile range
[IQR]), and accuracy (root-mean-squared error [RMSE]) and clini-
cal robustness, by calculating the proportion of patients with an
absolute percentage error greater than 20% (1-P20) for eGFR; 95%
confidence intervals and P values were approximated using
bootstrap resampling (18).
Data from 3786 patients were included: A total of 3484
patients had solid cancer, 136 had hematological cancer, and 166
had a noncancer diagnosis (Table 1). Creatinine values and mGFR
were obtained the same day for 27% and within 1 week for 89%
of patients (Supplementary Figure S1, available online). The me-
dian mGFR was 85 mL/min (IQR ¼ 61–109 mL/min). The median
serum creatinine value was 0.95 mg/dL (IQR ¼ 0.83–1.11 mg/dL).
The median age, height, weight and BSA were 60 years, 169 cm,
74 kg, and 1.85 m2 respectively (Table 2). Center-specific sum-
mary statistics are provided in Supplementary Figures S2–S4 and
Supplementary Tables S2–S3, available online.
CamGFR was statistically significantly more accurate in esti-
mating GFR than all other models, both by RMSE or 1-P20, fol-
lowed by the CKD-EPI model (Figure 1, Supplementary Figure S6
and Supplementary Table S5, available online). The RMSE for
the CamGFR model was 17.3 mL/min (confidence interval [CI] =
16.7 to 17.9 mL/min) and 18.2 mL/min (CI = 17.6 to 18.7 mL/min)
for the CKD-EPI model (P ¼ .03) and the 1-P20 results for
CamGFR were 0.295 (CI = 0.280 to 0.309) and 0.318 (CI = 0.303 to
0.333) for CKD-EPI, respectively (P ¼ .03). In subgroup analyses,
CamGFR was the most accurate model for most patient sub-
groups divided by tumor type, age, BSA, serum creatinine, or
sex (Supplementary Figures S7–S10, available online).
Finally, CamGFR had the lowest RMSE both for male and fe-
male patients and in six out of seven centers. Model perfor-
mance was not consistent between centers (Supplementary
Table S5, available online, Figure 1), probably reflecting differen-
ces in non-IDMS–creatinine values (Supplementary Figure S3,
available online).
We did not adjust the CamGFR model to include race as a po-
tential variable for two reasons: the small number of black
patients (n¼ 22) and the absence of a statistically significant dif-
ference in BSA, mGFR, or serum creatinine when we compared
10 random data draws matched for age and sex between non-
black and black patients (Supplementary Figure S5 and
Supplementary Table S4, available online). Other studies have
documented systematic differences for the relationship be-
tween eGFR and creatinine for black patients (14,15), and our
study is probably underpowered to detect this. The use of non-
IDMS–creatinine data in this study represents a further limita-
tion (19). Differences between non-IDMS and IDMS creatinine
exist (2), and future work should expand the CamGFR model to
Table 1. Characteristics of study patients: summary of categorical variables split by center
Center Total Solid cancer Hematological cancer Noncancer Female Race, black
Cambridge 404 227 114 63 198 6
Edinburgh 597 472 22 103 245 0
London-Barts 108 108 0 0 0 0
Manchester 1777 1777 0 0 1066 16
Melbourne 308 308 0 0 111 0
Southampton 436 436 0 0 0 0
Wales 156 156 0 0 89 0
Total 3786 3484 136 166 1709 22
Table 2. Characteristics of study patients: summary of continuous variables for all patients*
Variable Mean SD Minimum Q1 Median Q3 Maximum
GFR, mL/min 86 32 9 61 85 109 209
Creatinine, mg/dL 0.99 0.28 0.43 0.83 0.95 1.11 4.45
Age, years 57 16 18 45 60 70 91
Weight, kg 76 19 33 63 74 87 200
Height, cm 169 11 137 160 169 177 204
BSA, m2 1.85 0.25 1.17 1.68 1.85 2.02 3.17
*GFR was measured using either 99mTc-DTPA (Edinburgh and Melbourne) or 51Cr-EDTA (all others). 51Cr-EDTA ¼ chromium-51–labeled ethylenediamine tetraacetic
acid; GFR ¼ glomerular filtration rate; BSA ¼ body surface area (calculated using DuBois and DuBois); Q1 ¼ 25th percentile; Q3 ¼ 75th percentile; 99mTc-DTPA = 99mTc-
diethylenetriaminepentaacetic acid.
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IDMS–creatinine data use. Of note, the CKD-EPI model was de-
veloped for use with IDMS–creatinine measurements specifi-
cally, but it still outperformed other models that have been
developed with non-IDMS data.
The data were mostly from chemotherapy treatment–naive
patients with cancer, and the longitudinal effect of treatment on
eGFR requires further study. Probably attributable to the near-
normal renal function of the majority of the patients in our
study, we find that the underlying diagnosis of the patients does
not affect the suitability of the models. CamGFR, developed on
data from patients with cancer, performs best in noncancer
patients, and CKD-EPI, developed on data from patients without
cancer, performs well for data from patients with cancer.
This work is based on data from seven centers, and it con-
firms that of the available models, the CamGFR model
estimates GFR most accurately, but the CKD-EPI model per-
forms nearly as well overall and across the spectrum of rele-
vant subgroups. The greatest gain in accuracy by these newer
models over the older models, such as Cockcroft-Gault and
Wright, was observed in younger patients and patients with
lower creatinine values, probably reflecting the differences in
model-development populations. However, even considering
the different patient populations in different centers, it is
likely that errors in estimating GFR can be reduced by stan-
dardizing the methods used to measure serum creatinine at
different laboratories and using appropriate models. Given the
linear relationship between GFR and carboplatin dose via the
Calvert equation (20), improved estimates of GFR using
CamGFR will translate into carboplatin prescriptions that are
more accurate.
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Figure 1. Performance analysis of commonly used and well-performing models. Results for the five best-performing models (CamGFR, CKD-EPI, Wright, MDRD-186, and
Cockcroft-Gault) for the 3776 patients from the non-IDMS–creatinine validation dataset are displayed. Performance analysis of the other models is included in
Supplementary Table S5 (available online). A pooled analysis of data from all centers and the individual center analyses are shown (first row). The residual (measured GFR–
estimated GFR) median, which is a measure of a model’s bias, is displayed (second row). The residual interquartile range (IQR), which is a measure of a model’s precision, is
displayed (third row). The RMSE, which is a measure of a model’s accuracy, is displayed. Accuracy is a combination metric of bias and precision (fourth row). The proportion
of patients who have an absolute percentage error more than 20% (1-P20), which reflects clinical robustness by illustrating the proportion of patients with a clinically rele-
vant error, is displayed. The best results are closest to zero for the residual median and the smallest value for IQR, RMSE, and 1-P20. All error bars are 95% confidence inter-
vals calculated using bootstrap resampling with 2000 repetitions and a normal distribution approximation. CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration;
IDMS = isotope dilution mass spectrometry; MDRD-186 = Modification of Diet in Renal Disease version 186; RMSE = root-mean-squared error.
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